This article is more than 5 years old. Information may no longer be current.
Alimera signs agreement with MEAgate to distribute Iluvien in Middle East
Click Here to Manage Email Alerts
Alimera Sciences B.V., a subsidiary of Alimera Sciences, has signed an agreement with MEAgate International FZLLC to distribute Iluvien to treat diabetic macular edema in several Middle Eastern countries.
According to the terms of the agreement, MEAgate will open a scientific office for Alimera in the Middle East to support regulatory, medical affairs, and sales and marketing operations, a press release said.
MEAgate plans to have an initial team of five medical science liaisons to support Named Patient Sales, which are expected to begin this year in Saudi Arabia, Egypt, the United Arab Emirates and Lebanon. Named Patient Sales is an early access program designed to allow health authorities to provide globally approved medications to patients while the products are in the process of approval and registration.
MEAgate plans to assist Alimera in registering Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) in the 11 countries included in the agreement: Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, UAE and Yemen.